65,437 trials
Heartburn
Primary: Complete Heartburn Relief During the First Full 24-Hour Period in Intent-to-Treat (ITT) Population — 100; 121 Participants
Type 2 Diabetes Mellitus
Primary: Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment — -3.9; -75.3; 7.0; 74.6 picomoles/L per minute (pmol/L*min) — p=0.376
Renal Failure
Primary: Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death) — 396; 408 Participants
Major Depressive Disorder
Primary: Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score — -22.4; -18.4 Change in total score at endpoint — p=0.022
Diabetes Mellitus Type 2
Primary: Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) — 8.79; 8.77; -1.52; -1.31 percent of HbA1c — p=0.026
Carcinoma, Renal Cell
Primary: Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST) — 35 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) — 8.70; 8.69; -1.46; -1.41 percent of HbA1c — p=0.551
Fibromyalgia
Primary: Composite Syndrome Responder Status — 56; 103 Syndrome Responder Participants — p=<0.001
Proteinuria
Primary: Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12 — -35.80; 1.37 Percent Change in Pr/Cr — p=0.001
Osteoarthritis · Chronic Pain
Primary: Mean Change From Randomization to 12 Weeks Following Randomization in Diary Brief Pain Inventory Score of Average Pain (Daily Scores of Average Pain Averaged Over 7…
Hepatitis C, Chronic
Primary: Sustained Virologic Response (SVR) Rate — 39.8; 38.0; 40.9 Percentage of participants — p=0.567
Pain
Primary: Subjects With Treatment Emergent Adverse Events — 378 participants
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo — 17.86; 18.29; 17.83; -2.36 total…
Influenza
Primary: Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-Vaccination With Fluzone® — 15; 7; 0; 2 Percentage of Participants
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL) — 292; 100…